BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Licht C, Weyersberg A, Heinen S, Stapenhorst L, Devenge J, Beck B, Waldherr R, Kirschfink M, Zipfel PF, Hoppe B. Successful plasma therapy for atypical hemolytic uremic syndrome caused by factor H deficiency owing to a novel mutation in the complement cofactor protein domain 15. Am J Kidney Dis 2005;45:415-21. [PMID: 15685522 DOI: 10.1053/j.ajkd.2004.10.018] [Cited by in Crossref: 94] [Cited by in F6Publishing: 71] [Article Influence: 5.5] [Reference Citation Analysis]
Number Citing Articles
1 Noris M, Remuzzi G. Genetics and Genetic Testing in Hemolytic Uremic Syndrome/Thrombotic Thrombocytopenic Purpura. Seminars in Nephrology 2010;30:395-408. [DOI: 10.1016/j.semnephrol.2010.06.006] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 1.9] [Reference Citation Analysis]
2 Heinen S, Pluthero FG, van Eimeren VF, Quaggin SE, Licht C. Monitoring and modeling treatment of atypical hemolytic uremic syndrome. Mol Immunol 2013;54:84-8. [PMID: 23220071 DOI: 10.1016/j.molimm.2012.10.044] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 1.8] [Reference Citation Analysis]
3 Nathanson S, Ulinski T, Frémeaux-Bacchi V, Deschênes G. Secondary failure of plasma therapy in factor H deficiency. Pediatr Nephrol 2006;21:1769-71. [PMID: 16909242 DOI: 10.1007/s00467-006-0237-9] [Cited by in Crossref: 28] [Cited by in F6Publishing: 22] [Article Influence: 1.8] [Reference Citation Analysis]
4 Michelfelder S, Parsons J, Bohlender LL, Hoernstein SNW, Niederkrüger H, Busch A, Krieghoff N, Koch J, Fode B, Schaaf A, Frischmuth T, Pohl M, Zipfel PF, Reski R, Decker EL, Häffner K. Moss-Produced, Glycosylation-Optimized Human Factor H for Therapeutic Application in Complement Disorders. J Am Soc Nephrol 2017;28:1462-74. [PMID: 27932477 DOI: 10.1681/ASN.2015070745] [Cited by in Crossref: 24] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
5 Kim JJ, Goodship THJ, Tizard J, Inward C. Plasma therapy for atypical haemolytic uraemic syndrome associated with heterozygous factor H mutations. Pediatr Nephrol 2011;26:2073-6. [DOI: 10.1007/s00467-011-1944-4] [Cited by in Crossref: 24] [Cited by in F6Publishing: 16] [Article Influence: 2.2] [Reference Citation Analysis]
6 Pickering MC, D'Agati VD, Nester CM, Smith RJ, Haas M, Appel GB, Alpers CE, Bajema IM, Bedrosian C, Braun M, Doyle M, Fakhouri F, Fervenza FC, Fogo AB, Frémeaux-Bacchi V, Gale DP, Goicoechea de Jorge E, Griffin G, Harris CL, Holers VM, Johnson S, Lavin PJ, Medjeral-Thomas N, Paul Morgan B, Nast CC, Noel LH, Peters DK, Rodríguez de Córdoba S, Servais A, Sethi S, Song WC, Tamburini P, Thurman JM, Zavros M, Cook HT. C3 glomerulopathy: consensus report. Kidney Int 2013;84:1079-89. [PMID: 24172683 DOI: 10.1038/ki.2013.377] [Cited by in Crossref: 356] [Cited by in F6Publishing: 297] [Article Influence: 39.6] [Reference Citation Analysis]
7 Zhang L, Zhang Q. Glycated Plasma Proteins as More Sensitive Markers for Glycemic Control in Type 1 Diabetes. Proteomics Clin Appl 2020;14:e1900104. [PMID: 31868294 DOI: 10.1002/prca.201900104] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
8 Greenbaum LA. Atypical Hemolytic Uremic Syndrome. Advances in Pediatrics 2014;61:335-56. [DOI: 10.1016/j.yapd.2014.04.001] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
9 Smith RJH, Appel GB, Blom AM, Cook HT, D'Agati VD, Fakhouri F, Fremeaux-Bacchi V, Józsi M, Kavanagh D, Lambris JD, Noris M, Pickering MC, Remuzzi G, de Córdoba SR, Sethi S, Van der Vlag J, Zipfel PF, Nester CM. C3 glomerulopathy - understanding a rare complement-driven renal disease. Nat Rev Nephrol 2019;15:129-43. [PMID: 30692664 DOI: 10.1038/s41581-018-0107-2] [Cited by in Crossref: 81] [Cited by in F6Publishing: 65] [Article Influence: 27.0] [Reference Citation Analysis]
10 Saland JM, Ruggenenti P, Remuzzi G. Liver-kidney transplantation to cure atypical hemolytic uremic syndrome. J Am Soc Nephrol. 2009;20:940-949. [PMID: 19092117 DOI: 10.1681/asn.2008080906] [Cited by in Crossref: 127] [Cited by in F6Publishing: 51] [Article Influence: 9.1] [Reference Citation Analysis]
11 Saikia B, Vashisht N, Gupta N, Sharma A. Exchange transfusion for neonate with haemolytic uremic syndrome. Springerplus 2016;5:52. [PMID: 26835232 DOI: 10.1186/s40064-016-1667-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
12 Schick T, Steinhauer M, Aslanidis A, Altay L, Karlstetter M, Langmann T, Kirschfink M, Fauser S. Local complement activation in aqueous humor in patients with age-related macular degeneration. Eye (Lond) 2017;31:810-3. [PMID: 28128795 DOI: 10.1038/eye.2016.328] [Cited by in Crossref: 39] [Cited by in F6Publishing: 40] [Article Influence: 7.8] [Reference Citation Analysis]
13 Jodele S, Laskin BL, Dandoy CE, Myers KC, El-Bietar J, Davies SM, Goebel J, Dixon BP. A new paradigm: Diagnosis and management of HSCT-associated thrombotic microangiopathy as multi-system endothelial injury. Blood Rev 2015;29:191-204. [PMID: 25483393 DOI: 10.1016/j.blre.2014.11.001] [Cited by in Crossref: 155] [Cited by in F6Publishing: 138] [Article Influence: 19.4] [Reference Citation Analysis]
14 Cavero T, Alonso M. Where are we with haemolytic uremic syndrome? Med Clin (Barc) 2018;151:329-35. [PMID: 29699703 DOI: 10.1016/j.medcli.2018.02.016] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
15 Rosove MH. Thrombotic microangiopathies. Seminars in Arthritis and Rheumatism 2014;43:797-805. [DOI: 10.1016/j.semarthrit.2013.11.004] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 2.9] [Reference Citation Analysis]
16 Johnson S, Taylor CM. Hemolytic Uremic Syndrome. In: Avner E, Harmon W, Niaudet P, Yoshikawa N, editors. Pediatric Nephrology. Berlin: Springer Berlin Heidelberg; 2009. pp. 1155-80. [DOI: 10.1007/978-3-540-76341-3_48] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
17 Nester CM, Smith RJ. Treatment options for C3 glomerulopathy. Curr Opin Nephrol Hypertens. 2013;22:231-237. [PMID: 23318699 DOI: 10.1097/mnh.0b013e32835da24c] [Cited by in Crossref: 43] [Cited by in F6Publishing: 26] [Article Influence: 4.8] [Reference Citation Analysis]
18 Kerr H, Herbert AP, Makou E, Abramczyk D, Malik TH, Lomax-Browne H, Yang Y, Pappworth IY, Denton H, Richards A, Marchbank KJ, Pickering MC, Barlow PN. Murine Factor H Co-Produced in Yeast With Protein Disulfide Isomerase Ameliorated C3 Dysregulation in Factor H-Deficient Mice. Front Immunol 2021;12:681098. [PMID: 34054871 DOI: 10.3389/fimmu.2021.681098] [Reference Citation Analysis]
19 Jokiranta TS, Zipfel PF, Fremeaux-bacchi V, Taylor CM, Goodship TJ, Noris M. Where next with atypical hemolytic uremic syndrome? Molecular Immunology 2007;44:3889-900. [DOI: 10.1016/j.molimm.2007.06.003] [Cited by in Crossref: 43] [Cited by in F6Publishing: 37] [Article Influence: 2.9] [Reference Citation Analysis]
20 Lau KK, Smith RJ, Kolbeck PC, Butani L. Dense deposit disease and the factor H H402 allele. Clin Exp Nephrol 2008;12:228-32. [PMID: 18224273 DOI: 10.1007/s10157-008-0031-z] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
21 Olaciregui Echenique I, Areses Trapote R, Ubetagoyena Arrieta M, Sota Busselo I, García Pardos C, Echaniz Aizpuru P. [Incomplete hemolytic uremic syndrome associated with partial factor H deficiency]. An Pediatr (Barc) 2007;66:188-90. [PMID: 17306107 DOI: 10.1157/13098939] [Reference Citation Analysis]
22 Licht C, Schlötzer-schrehardt U, Kirschfink M, Zipfel PF, Hoppe B. MPGN II – genetically determined by defective complement regulation? Pediatr Nephrol 2007;22:2-9. [DOI: 10.1007/s00467-006-0299-8] [Cited by in Crossref: 32] [Cited by in F6Publishing: 20] [Article Influence: 2.1] [Reference Citation Analysis]
23 Hildebrand AM, Huang SS, Clark WF. Plasma Exchange for Kidney Disease: What Is the Best Evidence? Advances in Chronic Kidney Disease 2014;21:217-27. [DOI: 10.1053/j.ackd.2014.01.008] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
24 Michelfelder S, Fischer F, Wäldin A, Hörle KV, Pohl M, Parsons J, Reski R, Decker EL, Zipfel PF, Skerka C, Häffner K. The MFHR1 Fusion Protein Is a Novel Synthetic Multitarget Complement Inhibitor with Therapeutic Potential. J Am Soc Nephrol 2018;29:1141-53. [PMID: 29335241 DOI: 10.1681/ASN.2017070738] [Cited by in Crossref: 15] [Cited by in F6Publishing: 6] [Article Influence: 3.8] [Reference Citation Analysis]
25 Cochat P, Feber J. [What is new in pediatric nephrology?]. Arch Pediatr 2006;13:64-8. [PMID: 16310351 DOI: 10.1016/j.arcped.2005.10.009] [Cited by in Crossref: 3] [Article Influence: 0.2] [Reference Citation Analysis]
26 Loirat C, Noris M, Fremeaux-Bacchi V. Complement and the atypical hemolytic uremic syndrome in children. Pediatr Nephrol 2008;23:1957-72. [PMID: 18594873 DOI: 10.1007/s00467-008-0872-4] [Cited by in Crossref: 135] [Cited by in F6Publishing: 109] [Article Influence: 9.6] [Reference Citation Analysis]
27 Ariceta G, Besbas N, Johnson S, Karpman D, Landau D, Licht C, Loirat C, Pecoraro C, Taylor CM, Van de Kar N, Vandewalle J, Zimmerhackl LB; European Paediatric Study Group for HUS. Guideline for the investigation and initial therapy of diarrhea-negative hemolytic uremic syndrome. Pediatr Nephrol 2009;24:687-96. [PMID: 18800230 DOI: 10.1007/s00467-008-0964-1] [Cited by in Crossref: 225] [Cited by in F6Publishing: 173] [Article Influence: 16.1] [Reference Citation Analysis]
28 Würzner R, Zimmerhackl LB. Therapeutic strategies for atypical and recurrent hemolytic uremic syndromes (HUS). In: Zipfel PF, editor. Complement and Kidney Disease. Basel: Birkhäuser-Verlag; 2006. pp. 149-63. [DOI: 10.1007/3-7643-7428-4_9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
29 Loirat C, Saland J, Bitzan M. Management of hemolytic uremic syndrome. Presse Med. 2012;41:e115-e135. [PMID: 22284541 DOI: 10.1016/j.lpm.2011.11.013] [Cited by in Crossref: 69] [Cited by in F6Publishing: 45] [Article Influence: 6.9] [Reference Citation Analysis]
30 Yang Y, Denton H, Davies OR, Smith-Jackson K, Kerr H, Herbert AP, Barlow PN, Pickering MC, Marchbank KJ. An Engineered Complement Factor H Construct for Treatment of C3 Glomerulopathy. J Am Soc Nephrol 2018;29:1649-61. [PMID: 29588430 DOI: 10.1681/ASN.2017091006] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 5.5] [Reference Citation Analysis]
31 Zhang Y, Keenan A, Dai DF, May KS, Anderson EE, Lindorfer MA, Henrich JB, Pitcher GR, Taylor RP, Smith RJ. C3(H2O) prevents rescue of complement-mediated C3 glomerulopathy in Cfh-/- Cfd-/- mice. JCI Insight 2020;5:135758. [PMID: 32376801 DOI: 10.1172/jci.insight.135758] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
32 Boon CJ, van de Kar NC, Klevering BJ, Keunen JE, Cremers FP, Klaver CC, Hoyng CB, Daha MR, den Hollander AI. The spectrum of phenotypes caused by variants in the CFH gene. Molecular Immunology 2009;46:1573-94. [DOI: 10.1016/j.molimm.2009.02.013] [Cited by in Crossref: 61] [Cited by in F6Publishing: 58] [Article Influence: 4.7] [Reference Citation Analysis]
33 Ricklin D. Manipulating the mediator: modulation of the alternative complement pathway C3 convertase in health, disease and therapy. Immunobiology 2012;217:1057-66. [PMID: 22964231 DOI: 10.1016/j.imbio.2012.07.016] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 3.3] [Reference Citation Analysis]
34 Wang F, Yu F, Zhao M. A method of purifying intact complement factor H from human plasma. Protein Expression and Purification 2013;91:105-11. [DOI: 10.1016/j.pep.2013.07.014] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
35 Al-Akash SI, Almond PS, Savell VH, Gharaybeh SI, Hogue C. Eculizumab induces long-term remission in recurrent post-transplant HUS associated with C3 gene mutation. Pediatr Nephrol. 2011;26:613-619. [PMID: 21125405 DOI: 10.1007/s00467-010-1708-6] [Cited by in Crossref: 76] [Cited by in F6Publishing: 67] [Article Influence: 6.3] [Reference Citation Analysis]
36 Loirat C, Frémeaux-Bacchi V. Atypical hemolytic uremic syndrome. Orphanet J Rare Dis 2011;6:60. [PMID: 21902819 DOI: 10.1186/1750-1172-6-60] [Cited by in Crossref: 375] [Cited by in F6Publishing: 304] [Article Influence: 34.1] [Reference Citation Analysis]
37 Sellier-Leclerc AL, Fremeaux-Bacchi V, Dragon-Durey MA, Macher MA, Niaudet P, Guest G, Boudailliez B, Bouissou F, Deschenes G, Gie S, Tsimaratos M, Fischbach M, Morin D, Nivet H, Alberti C, Loirat C; French Society of Pediatric Nephrology. Differential impact of complement mutations on clinical characteristics in atypical hemolytic uremic syndrome. J Am Soc Nephrol. 2007;18:2392-2400. [PMID: 17599974 DOI: 10.1681/asn.2006080811] [Cited by in Crossref: 272] [Cited by in F6Publishing: 121] [Article Influence: 18.1] [Reference Citation Analysis]
38 Waters AM, Licht C. aHUS caused by complement dysregulation: new therapies on the horizon. Pediatr Nephrol. 2011;26:41-57. [PMID: 20556434 DOI: 10.1007/s00467-010-1556-4] [Cited by in Crossref: 87] [Cited by in F6Publishing: 74] [Article Influence: 7.3] [Reference Citation Analysis]
39 Seitz B, Albano L, Vocila F, Mzoughi S, Aoudia R, Guitard J, Ribes D, Vachet-Copponat H, Mourad G, Bienaimé F, Dahan P, Frémeaux-Bacchi V, Cassuto E. Recurrence of hemolytic uremic syndrome after renal transplantation. Transplant Proc 2007;39:2583-5. [PMID: 17954182 DOI: 10.1016/j.transproceed.2007.08.021] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 0.9] [Reference Citation Analysis]
40 Gnappi E, Allinovi M, Vaglio A, Bresin E, Sorosina A, Pilato FP, Allegri L, Manenti L. Membrano-proliferative glomerulonephritis, atypical hemolytic uremic syndrome, and a new complement factor H mutation: report of a case. Pediatr Nephrol 2012;27:1995-9. [DOI: 10.1007/s00467-012-2210-0] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
41 Loirat C, Fremeaux-Bacchi V. Hemolytic uremic syndrome recurrence after renal transplantation. Pediatr Transplant. 2008;12:619-629. [PMID: 18482212 DOI: 10.1111/j.1399-3046.2008.00910.x] [Cited by in Crossref: 85] [Cited by in F6Publishing: 57] [Article Influence: 6.1] [Reference Citation Analysis]
42 Ponticelli C, Glassock RJ. Posttransplant recurrence of primary glomerulonephritis. Clin J Am Soc Nephrol. 2010;5:2363-2372. [PMID: 21030574 DOI: 10.2215/cjn.06720810] [Cited by in Crossref: 158] [Cited by in F6Publishing: 54] [Article Influence: 13.2] [Reference Citation Analysis]
43 Pickering MC, de Jorge EG, Martinez-Barricarte R, Recalde S, Garcia-Layana A, Rose KL, Moss J, Walport MJ, Cook HT, de Córdoba SR. Spontaneous hemolytic uremic syndrome triggered by complement factor H lacking surface recognition domains. J Exp Med. 2007;204:1249-1256. [PMID: 17517971 DOI: 10.1084/jem.20070301] [Cited by in Crossref: 201] [Cited by in F6Publishing: 180] [Article Influence: 13.4] [Reference Citation Analysis]
44 Cho HY, Lee BS, Moon KC, Ha IS, Cheong HI, Choi Y. Complete factor H deficiency-associated atypical hemolytic uremic syndrome in a neonate. Pediatr Nephrol 2007;22:874-80. [PMID: 17295030 DOI: 10.1007/s00467-007-0438-x] [Cited by in Crossref: 33] [Cited by in F6Publishing: 26] [Article Influence: 2.2] [Reference Citation Analysis]
45 Zipfel PF, Skerka C. Complement dysfunction in hemolytic uremic syndrome. Curr Opin Rheumatol 2006;18:548-55. [PMID: 16896298 DOI: 10.1097/01.bor.0000240370.47336.ae] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 1.1] [Reference Citation Analysis]
46 Gaggl M, Aigner C, Csuka D, Szilágyi Á, Prohászka Z, Kain R, Haninger N, Knechtelsdorfer M, Sunder-Plassmann R, Sunder-Plassmann G, Schmidt A. Maternal and Fetal Outcomes of Pregnancies in Women with Atypical Hemolytic Uremic Syndrome. J Am Soc Nephrol 2018;29:1020-9. [PMID: 29282226 DOI: 10.1681/ASN.2016090995] [Cited by in Crossref: 28] [Cited by in F6Publishing: 19] [Article Influence: 5.6] [Reference Citation Analysis]
47 Ruseva MM, Peng T, Lasaro MA, Bouchard K, Liu-Chen S, Sun F, Yu ZX, Marozsan A, Wang Y, Pickering MC. Efficacy of Targeted Complement Inhibition in Experimental C3 Glomerulopathy. J Am Soc Nephrol 2016;27:405-16. [PMID: 26047789 DOI: 10.1681/ASN.2014121195] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 2.1] [Reference Citation Analysis]
48 Skattum L, van Deuren M, van der Poll T, Truedsson L. Complement deficiency states and associated infections. Mol Immunol 2011;48:1643-55. [PMID: 21624663 DOI: 10.1016/j.molimm.2011.05.001] [Cited by in Crossref: 150] [Cited by in F6Publishing: 117] [Article Influence: 13.6] [Reference Citation Analysis]
49 Heeringa SF, Cohen CD. Kidney diseases caused by complement dysregulation: acquired, inherited, and still more to come. Clin Dev Immunol. 2012;2012:695131. [PMID: 23227086 DOI: 10.1155/2012/695131] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
50 Shatzel JJ, Taylor JA. Syndromes of Thrombotic Microangiopathy. Med Clin North Am 2017;101:395-415. [PMID: 28189178 DOI: 10.1016/j.mcna.2016.09.010] [Cited by in Crossref: 35] [Cited by in F6Publishing: 22] [Article Influence: 5.8] [Reference Citation Analysis]
51 Saland JM, Shneider BL, Bromberg JS, Shi PA, Ward SC, Magid MS, Benchimol C, Seikaly MG, Emre SH, Bresin E, Remuzzi G. Successful split liver-kidney transplant for factor H associated hemolytic uremic syndrome. Clin J Am Soc Nephrol. 2009;4:201-206. [PMID: 19005013 DOI: 10.2215/cjn.02170508] [Cited by in Crossref: 53] [Cited by in F6Publishing: 21] [Article Influence: 3.8] [Reference Citation Analysis]
52 Lapeyraque AL, Wagner E, Phan V, Clermont MJ, Merouani A, Frémeaux-Bacchi V, Goodship TH, Robitaille P. Efficacy of plasma therapy in atypical hemolytic uremic syndrome with complement factor H mutations. Pediatr Nephrol 2008;23:1363-6. [PMID: 18425537 DOI: 10.1007/s00467-008-0803-4] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 1.2] [Reference Citation Analysis]
53 Skerka C, Józsi M. Role of complement and Factor H in hemolytic uremic syndrome. In: Zipfel PF, editor. Complement and Kidney Disease. Basel: Birkhäuser-Verlag; 2006. pp. 85-109. [DOI: 10.1007/3-7643-7428-4_6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
54 Laskin BL, Goebel J, Davies SM, Jodele S. Small vessels, big trouble in the kidneys and beyond: hematopoietic stem cell transplantation–associated thrombotic microangiopathy. Blood 2011;118:1452-62. [DOI: 10.1182/blood-2011-02-321315] [Cited by in Crossref: 193] [Cited by in F6Publishing: 163] [Article Influence: 17.5] [Reference Citation Analysis]
55 Martin SM, Balestracci A, Puyol I, Toledo I, Cao G, Arizeta G. Uncommon Presentation of Atypical Hemolytic Uremic Syndrome: A Case Report. Indian J Nephrol 2021;31:478-81. [PMID: 34880559 DOI: 10.4103/ijn.IJN_271_20] [Reference Citation Analysis]
56 Habbig S, Mihatsch MJ, Heinen S, Beck B, Emmel M, Skerka C, Kirschfink M, Hoppe B, Zipfel PF, Licht C. C3 deposition glomerulopathy due to a functional factor H defect. Kidney Int. 2009;75:1230-1234. [PMID: 18633337 DOI: 10.1038/ki.2008.354] [Cited by in Crossref: 69] [Cited by in F6Publishing: 51] [Article Influence: 4.9] [Reference Citation Analysis]
57 Smith RJ, Alexander J, Barlow PN, Botto M, Cassavant TL, Cook HT, de Córdoba SR, Hageman GS, Jokiranta TS, Kimberling WJ. New approaches to the treatment of dense deposit disease. J Am Soc Nephrol. 2007;18:2447-2456. [PMID: 17675665 DOI: 10.1681/asn.2007030356] [Cited by in Crossref: 187] [Cited by in F6Publishing: 95] [Article Influence: 12.5] [Reference Citation Analysis]
58 Licht C, Pluthero FG, Li L, Christensen H, Habbig S, Hoppe B, Geary DF, Zipfel PF, Kahr WH. Platelet-associated complement factor H in healthy persons and patients with atypical HUS. Blood 2009;114:4538-45. [PMID: 19704120 DOI: 10.1182/blood-2009-03-205096] [Cited by in Crossref: 54] [Cited by in F6Publishing: 49] [Article Influence: 4.2] [Reference Citation Analysis]
59 Makou E, Herbert AP, Barlow PN. Functional anatomy of complement factor H. Biochemistry. 2013;52:3949-3962. [PMID: 23701234 DOI: 10.1021/bi4003452] [Cited by in Crossref: 84] [Cited by in F6Publishing: 79] [Article Influence: 9.3] [Reference Citation Analysis]
60 Ferluga J, Kishore U, Sim RB. A potential anti-coagulant role of complement factor H. Molecular Immunology 2014;59:188-93. [DOI: 10.1016/j.molimm.2014.02.012] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.8] [Reference Citation Analysis]
61 Xie L, Nester CM, Reed AI, Zhang Y, Smith RJ, Thomas CP. Tailored eculizumab therapy in the management of complement factor H-mediated atypical hemolytic uremic syndrome in an adult kidney transplant recipient: a case report. Transplant Proc. 2012;44:3037-3040. [PMID: 23195022 DOI: 10.1016/j.transproceed.2012.07.141] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 2.9] [Reference Citation Analysis]
62 Saland JM, Emre SH, Shneider BL, Benchimol C, Ames S, Bromberg JS, Remuzzi G, Strain L, Goodship TH. Favorable long-term outcome after liver-kidney transplant for recurrent hemolytic uremic syndrome associated with a factor H mutation. Am J Transplant. 2006;6:1948-1952. [PMID: 16889549 DOI: 10.1111/j.1600-6143.2006.01375.x] [Cited by in Crossref: 94] [Cited by in F6Publishing: 83] [Article Influence: 5.9] [Reference Citation Analysis]
63 Loirat C, Fremeaux-bacchi V. Recurrence of haemolytic uraemic syndrome after renal transplantation. Current Opinion in Organ Transplantation 2007;12:496-502. [DOI: 10.1097/mot.0b013e3282ef3d64] [Reference Citation Analysis]
64 Ricklin D, Lambris JD. Progress and Trends in Complement Therapeutics. Adv Exp Med Biol 2013;735:1-22. [PMID: 22990692 DOI: 10.1007/978-1-4614-4118-2_1] [Cited by in Crossref: 93] [Cited by in F6Publishing: 78] [Article Influence: 9.3] [Reference Citation Analysis]
65 Master Sankar Raj V, Gordillo R, Chand DH. Overview of C3 Glomerulopathy. Front Pediatr 2016;4:45. [PMID: 27200326 DOI: 10.3389/fped.2016.00045] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
66 Massey HD, Mcpherson RA. Mediators of Inflammation. Henry's Clinical Diagnosis and Management by Laboratory Methods. Elsevier; 2011. pp. 914-32. [DOI: 10.1016/b978-1-4377-0974-2.00047-6] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
67 Ansari M, McKeigue PM, Skerka C, Hayward C, Rudan I, Vitart V, Polasek O, Armbrecht AM, Yates JR, Vatavuk Z, Bencic G, Kolcic I, Oostra BA, Van Duijn CM, Campbell S, Stanton CM, Huffman J, Shu X, Khan JC, Shahid H, Harding SP, Bishop PN, Deary IJ, Moore AT, Dhillon B, Rudan P, Zipfel PF, Sim RB, Hastie ND, Campbell H, Wright AF. Genetic influences on plasma CFH and CFHR1 concentrations and their role in susceptibility to age-related macular degeneration. Hum Mol Genet 2013;22:4857-69. [PMID: 23873044 DOI: 10.1093/hmg/ddt336] [Cited by in Crossref: 54] [Cited by in F6Publishing: 54] [Article Influence: 6.0] [Reference Citation Analysis]
68 Licht C, Heinen S, Józsi M, Löschmann I, Saunders RE, Perkins SJ, Waldherr R, Skerka C, Kirschfink M, Hoppe B, Zipfel PF. Deletion of Lys224 in regulatory domain 4 of Factor H reveals a novel pathomechanism for dense deposit disease (MPGN II). Kidney Int 2006;70:42-50. [PMID: 16612335 DOI: 10.1038/sj.ki.5000269] [Cited by in Crossref: 154] [Cited by in F6Publishing: 131] [Article Influence: 9.6] [Reference Citation Analysis]
69 Davin JC, Olie KH, Verlaak R, Horuz F, Florquin S, Weening JJ, Groothoff JW, Strain L, Goodship TH. Complement factor H-associated atypical hemolytic uremic syndrome in monozygotic twins: concordant presentation, discordant response to treatment. Am J Kidney Dis 2006;47:e27-30. [PMID: 16431247 DOI: 10.1053/j.ajkd.2005.11.007] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 1.6] [Reference Citation Analysis]
70 De S, Waters AM, Segal AO, Trautmann A, Harvey EA, Licht C. Severe atypical HUS caused by CFH S1191L--case presentation and review of treatment options. Pediatr Nephrol 2010;25:97-104. [PMID: 19856002 DOI: 10.1007/s00467-009-1306-7] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.3] [Reference Citation Analysis]
71 Fakhouri F, de Jorge EG, Brune F, Azam P, Cook HT, Pickering MC. Treatment with human complement factor H rapidly reverses renal complement deposition in factor H-deficient mice. Kidney Int 2010;78:279-86. [PMID: 20445496 DOI: 10.1038/ki.2010.132] [Cited by in Crossref: 65] [Cited by in F6Publishing: 59] [Article Influence: 5.4] [Reference Citation Analysis]
72 Abarrategui-Garrido C, Melgosa M, Peña-Carrión A, de Jorge EG, de Córdoba SR, López-Trascasa M, Sánchez-Corral P. Mutations in proteins of the alternative pathway of complement and the pathogenesis of atypical hemolytic uremic syndrome. Am J Kidney Dis 2008;52:171-80. [PMID: 18423815 DOI: 10.1053/j.ajkd.2008.01.026] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 1.4] [Reference Citation Analysis]
73 Fraison JB, Pernin V, Alméras C, Vetromile F, Frémeaux-Bacchi V, Mourad G. [Thrombotic microangiopathy following kidney transplantation revealing factors H and I deficiencies]. Rev Med Interne 2011;32:e81-3. [PMID: 20667630 DOI: 10.1016/j.revmed.2010.06.013] [Reference Citation Analysis]
74 Noris M, Remuzzi G. Translational mini-review series on complement factor H: therapies of renal diseases associated with complement factor H abnormalities: atypical haemolytic uraemic syndrome and membranoproliferative glomerulonephritis. Clin Exp Immunol 2008;151:199-209. [PMID: 18070148 DOI: 10.1111/j.1365-2249.2007.03558.x] [Cited by in Crossref: 22] [Cited by in F6Publishing: 15] [Article Influence: 1.5] [Reference Citation Analysis]
75 Medjeral-Thomas NR, O'Shaughnessy MM, O'Regan JA, Traynor C, Flanagan M, Wong L, Teoh CW, Awan A, Waldron M, Cairns T, O'Kelly P, Dorman AM, Pickering MC, Conlon PJ, Cook HT. C3 glomerulopathy: clinicopathologic features and predictors of outcome. Clin J Am Soc Nephrol 2014;9:46-53. [PMID: 24178974 DOI: 10.2215/CJN.04700513] [Cited by in Crossref: 121] [Cited by in F6Publishing: 59] [Article Influence: 13.4] [Reference Citation Analysis]